ES2575143T3 - Inhibidores de tienopiridina de la proteína quinasa C atípica - Google Patents

Inhibidores de tienopiridina de la proteína quinasa C atípica Download PDF

Info

Publication number
ES2575143T3
ES2575143T3 ES12795969.0T ES12795969T ES2575143T3 ES 2575143 T3 ES2575143 T3 ES 2575143T3 ES 12795969 T ES12795969 T ES 12795969T ES 2575143 T3 ES2575143 T3 ES 2575143T3
Authority
ES
Spain
Prior art keywords
optionally substituted
nr22r23
members
heterocycloalkyl
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12795969.0T
Other languages
English (en)
Spanish (es)
Inventor
Bruce D. Dorsey
Keith S. Learn
Emma L. MORRIS
Gregory R. Ott
Jonathan R. ROFFEY
Christelle N. SOUDY
Jason C. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Ignyta Inc
Original Assignee
Cancer Research Technology Ltd
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Ignyta Inc filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2575143T3 publication Critical patent/ES2575143T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12795969.0T 2011-11-23 2012-11-19 Inhibidores de tienopiridina de la proteína quinasa C atípica Active ES2575143T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
US201161563310P 2011-11-23
PCT/US2012/065831 WO2013078126A1 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase c

Publications (1)

Publication Number Publication Date
ES2575143T3 true ES2575143T3 (es) 2016-06-24

Family

ID=47295200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12795969.0T Active ES2575143T3 (es) 2011-11-23 2012-11-19 Inhibidores de tienopiridina de la proteína quinasa C atípica

Country Status (11)

Country Link
US (3) US9604994B2 (enExample)
EP (2) EP2782917B1 (enExample)
JP (1) JP6206926B2 (enExample)
CN (1) CN104053661B (enExample)
AU (2) AU2012340869B2 (enExample)
CA (1) CA2855446C (enExample)
ES (1) ES2575143T3 (enExample)
IL (1) IL232559B (enExample)
IN (1) IN2014CN04558A (enExample)
MX (1) MX355088B (enExample)
WO (1) WO2013078126A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
BR112014017021A8 (pt) * 2012-01-10 2017-07-04 Nimbus Iris Inc inibidores de irak e usos dos mesmos
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
IN2015DN00127A (enExample) 2012-07-11 2015-05-29 Nimbus Iris Inc
CA2890911A1 (en) 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20160092991A (ko) 2013-09-27 2016-08-05 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
EP3394056B1 (en) * 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
CA3066939A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMA STORAGE DISEASES
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法
CN116925098B (zh) * 2022-04-09 2026-02-17 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
ES2258476T3 (es) 1999-09-30 2006-09-01 Neurogen Corporation Ciertos heterociclos sustituidos con alquilendiaminas.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
CA2423981A1 (en) 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
JP2005516005A (ja) 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Gsk−3阻害剤として有用なピリミジンベースの化合物
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200410975A (en) 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
DE602004020070D1 (de) 2003-06-11 2010-10-07 Xention Ltd Thienopyrimidin-derivate als kaliumkanal-inhibitoren
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006010568A2 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
PL2041139T3 (pl) 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
AR064154A1 (es) * 2006-12-07 2009-03-18 Piramed Ltd Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
US8809346B2 (en) 2008-05-30 2014-08-19 Universite De Versailles-Saint-Quentin-En-Yvelines ANT-ligands molecules and biological applications
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
PL2493895T3 (pl) 2009-10-29 2017-10-31 Vectura Ltd Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
IL232559B (en) 2018-04-30
NZ625447A (en) 2015-09-25
US20170158706A1 (en) 2017-06-08
AU2017203725B2 (en) 2019-02-28
US10183950B2 (en) 2019-01-22
CN104053661A (zh) 2014-09-17
AU2012340869B2 (en) 2017-03-02
IL232559A0 (en) 2014-06-30
CN104053661B (zh) 2018-06-19
EP2782917B1 (en) 2016-03-02
CA2855446A1 (en) 2013-05-30
MX2014006233A (es) 2014-10-17
HK1202529A1 (zh) 2015-10-02
US20190106433A1 (en) 2019-04-11
US9604994B2 (en) 2017-03-28
EP3048106B1 (en) 2019-11-06
AU2017203725A1 (en) 2017-06-22
US20140323435A1 (en) 2014-10-30
AU2012340869A1 (en) 2014-06-19
CA2855446C (en) 2021-04-20
IN2014CN04558A (enExample) 2015-09-18
JP6206926B2 (ja) 2017-10-04
EP3048106A1 (en) 2016-07-27
EP2782917A1 (en) 2014-10-01
US10954251B2 (en) 2021-03-23
MX355088B (es) 2018-04-04
WO2013078126A1 (en) 2013-05-30
JP2014533728A (ja) 2014-12-15

Similar Documents

Publication Publication Date Title
ES2575143T3 (es) Inhibidores de tienopiridina de la proteína quinasa C atípica
AU2019264475B2 (en) Bcl-2 inhibitors
AU2018256459B2 (en) Indole AHR inhibitors and uses thereof
ES2829636T3 (es) Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
ES2575710T3 (es) Derivados de pirrolopirimidina y purina
AU2022371727A1 (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
AU2019356011B2 (en) Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors
BR112020003676A2 (pt) compostos de pirazolopirimidinona e usos dos mesmos
JP6199316B2 (ja) 1H−ピロロ[2,3−b]ピリジン誘導体およびキナーゼ阻害剤としてのその使用
BR112020022006A2 (pt) piridazinonas como inibidores de parp7
KR20230097015A (ko) Mas-관련 G-단백질 수용체 X2의 조절제 및 관련 생성물 및 방법
BR112019004586A2 (pt) derivados de pirazolopiridina como moduladores de hpk1 e usos dos mesmos para o tratamento de câncer
EP4267553A1 (en) Modulators of mas-related g-protein receptor x2 and related products and methods
AU2013334236A1 (en) Heteroaryl inhibitors of PDE4
CA2754457A1 (en) Quinoxaline compounds
JP2019512535A (ja) Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
KR20160086404A (ko) Mknk1 및 mknk2 억제제로서의 티에노피리미딘
CN121002021A (zh) 三环杂环衍生物及其组合物和应用
EP3365346A1 (en) Oxa-diazaspiro compounds having activity against pain
NZ625447B2 (en) Thienopyrimidine inhibitors of atypical protein kinase c
HK1202529B (en) Thienopyrimidine inhibitors of atypical protein kinase c
OA16753A (en) Pyrrolopyrimidine and purine derivatives.